dermatologyadvisor6h
Bimzelx Approval Expanded to Include 3 Types of Inflammatory Arthritis
The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.
The Pharma Letter6h
2seventy bio and BMS to drop KarMMa-9 study
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx), an ...
The Pharma Letter20h
UCB maintains momentum with Bimzelx in psoriasis
Belgian drugmaker UCB (Euronext: UCB) has announced the presentation of new four-year data in patients with moderate to ...